about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Roche's I/O 2.0 dreams take a hit as TIG­IT in­hibitor fails PhI­II

4 years ago
R&D

As shares sky­rock­et on Sanofi deal, IGM Bio­sciences looks to bag $200M

4 years ago
Financing

In a twist, cell ther­a­py de­vel­op­er sees C-suite ex­o­dus while slash­ing costs

4 years ago
People

Paul Hud­son spells out new $6.15B tech­nol­o­gy play as Sanofi goes drug hunt­ing in on­col­o­gy, im­munol­o­gy

4 years ago
Deals

Slammed with fresh clin­i­cal fail­ure, Bio­gen and Io­n­is dis­card ear­ly-stage ALS can­di­date

4 years ago
R&D

Spe­cial­ty phar­ma play­er snaps up Aca­cia and its 2 drugs for a handy $100M

4 years ago
Deals

ALS drug sets the stage for fresh FDA de­bate; Im­plo­sions every­where you look; Big names turn up at biotechs; and more

4 years ago
Weekly

No more ac­cel­er­at­ed ap­provals for PI3K? Biotech cites FDA's 'cur­rent po­si­tion' as it warns of ma­jor de­lay

4 years ago
FDA+

As­traZeneca’s Imfinzi stum­bles in cer­vi­cal can­cer, leav­ing Mer­ck’s Keytru­da dom­i­nant

4 years ago
R&D
Pharma

Drug dis­cov­ery spe­cial­ists at Lig­and take their an­ti­body biz pub­lic via SPAC, aim­ing to build $850M com­pa­ny

4 years ago
Deals

PhI­II fail­ure trig­gers lay­offs, spend­ing cuts and warn­ing of 'dis­so­lu­tion' for sin­gle-mind­ed biotech

4 years ago
R&D

With lat­est Keytru­da OK, Mer­ck edges in­to Glax­o­SmithK­line’s (small) PD-1 turf

4 years ago
Pharma
FDA+

Putting Bio­gen's Aduhelm cri­sis be­hind him, Al San­drock grabs CEO role at gene ther­a­py play­er to lead turn­around ...

4 years ago
People

Tonix's lead drug fails PhI­II again, send­ing stock even clos­er to ze­ro

4 years ago
R&D

Small RSV con­tender eyes 'first-to-mar­ket' op­por­tu­ni­ty with $225M Asia deal

4 years ago
Deals
China

Mer­ck? Check. Roche? Check. Now Bris­tol My­ers Squibb wants As­traZeneca to pay for PD-L1 patents

4 years ago
Pharma
Law

Lat­est news on first-ever Lag-3 OK; Aduhelm sup­port, crit­i­cism both crescen­do; Phar­ma gets firm about Rus­sia; ...

4 years ago
Weekly

Go­ing against the cur­rent, Sor­ren­to spins out pain-fo­cused sub­sidiary in $140M SPAC deal

4 years ago
Deals

Mar­tin Shkre­li can't de­lay $25M pay­ment over an­ti­com­pet­i­tive case, judge rules

4 years ago
People

Hot on Roche’s heels, Mer­ck spells out mixed Keytru­da da­ta in ad­ju­vant NSCLC

4 years ago
R&D
Pharma

Chi­na work­ing on con­ces­sions to help home­grown com­pa­nies stay on US ex­changes — re­port

4 years ago
China
FDA+

Bio­gen los­es an­oth­er bid to re­vive Tec­fidera patent as gener­ic keeps eat­ing in­to block­buster sales

4 years ago
Pharma
Law

As­traZeneca shells out $775M to set­tle Ul­tomiris patent suit with Roche

4 years ago
Pharma
Law

Biotech founders sen­tenced to 1 year and 1 day for steal­ing Genen­tech se­crets, ly­ing to in­vestors

4 years ago
People
Law
First page Previous page 34353637383940 Next page Last page
A service from the Financial Times